SCHEMBL3016441

SCHEMBL3016441

COc1cc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(F)cc4)CC3)n2)cc(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.62
HSD17B10 Q99714 2/20 0.62
USP2 O75604 1/20 0.62
RECQL P46063 1/20 0.62
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
KMT2A Q03164 3/20 0.48
PKM P14618 3/20 0.47
MAPK1 P28482 2/20 0.44
GBA1 P04062 1/20 0.44
LMNA P02545 3/20 0.43
TSHR P16473 2/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
KDM4E B2RXH2 1/20 0.43
APAF1 O14727 1/20 0.43
HPGD P15428 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011244 0.92 MAPT (0.70) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3007698 0.91 MAPT (0.61) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3023042 0.91 USP2 (0.52) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3004407 0.90 MAPT (0.51) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3015817 0.90 LMNA (0.51) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3006933 0.90 MAPT (0.55) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3017677 0.90 USP2 (0.50) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3013624 0.89 HSD17B10 (0.50) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3015441 0.89 HSD17B10 (0.50) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3007158 0.89 MAPT (0.56) MAPTHSD17B10USP2RECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.